Efficacy and tolerability of a combined moxifloxacin/dexamethasone formulation for topical prophylaxis and reduction of inflammation in phacoemulsification: a comparative, double masked clinical trial

References

• Miller JJ, Scott IU, Flynn HW Jr, et al. Acute-onset endophthalmitis after cataract surgery (2000–2004): incidence, clinical settings, and visual acuity outcomes after treatment. Am J Ophthalmol 2005;139:983–7
   PubMed Web of Science ®Google Scholar
• Mollan SP, Gao A, Lockwood A, et al. Postcataract endophthalmitis: incidence and microbial isolates in a United Kingdom region from 1996 through 2004. J Cataract Refract Surg 2007;33:265–8
   PubMed Web of Science ®Google Scholar
• Wong TY, Chee SP. The epidemiology of acute endophthalmitis after cataract surgery in an Asian population. Ophthalmology 2004;111:699–705
   PubMed Web of Science ®Google Scholar
• Lalitha P, Rajagopalan J, Prakash K, et al. Postcataract endo phthalmitis in South India: incidence and outcome. Ophthalmology 2005;112:1884–9
   PubMed Web of Science ®Google Scholar
• Lundstrom M, Wejde G, Stenevi U, et al. Endophthalmitis after cataract surgery: a nationwide prospective study evaluating incidence in relation to incision type and location. Ophthalmology 2007;114:866–70 [Epub ahead of print 26 Feb 2007]
   Google Scholar
• Rosha DS, Ng JQ, Morlet N, et al. Cataract surgery practice and endophthalmitis prevention by Australian and New Zealand ophthalmologists. Clin Experiment Ophthalmol 2006;34:535–44
   PubMed Web of Science ®Google Scholar
• Kowalski RP, Romanowski EG, Mah FS, et al. Topical prophylaxis with moxifloxacin prevents endophthalmitis in a rabbit model. Am J Ophthalmol 2004;138:33–7
   PubMed Web of Science ®Google Scholar
• Mather R, Stewart JM, Prabriputaloong T, et al. The effect of cataract surgery on ocular levels of topical moxifloxacin. Am J Ophthalmol 2004;138:554–9
   PubMed Web of Science ®Google Scholar
• Ou JI, Ta CN. Endophthalmitis prophylaxis. Ophthalmol Clin North Am 2006;19:449–56
   PubMedGoogle Scholar
• Gordon-Bennett P, Karas A, Flanagan D, et al. A survey of measures used for the prevention of postoperative endophthalmitis after cataract surgery in the United Kingdom. Eye 2006 [Epub ahead of print 15 Dec 2006]
   Google Scholar
• Arbisser LB. Safety of intracameral moxifloxacin for endophthalmitis prophylaxis during cataract surgery. Accepted for presentation at the American Society of Cataract and Refractive Surgery, April 2007, San Diego, CA, USA
   Google Scholar
• Espiritu CR, Caparas VL, Bolinao JG. Safety of prophylactic intracameral moxifloxacin 0.5% ophthalmic solution in cataract surgery patients. J Cataract Refract Surg 2007;33: 63–8
   Google Scholar
• Arshinoff SA. Advantages and use of intracameral moxifloxacin for bacterial prophylaxis in cataract surgery. Accepted for presentation at the American Society of Cataract and Refractive Surgery, April 2007, San Diego, CA, USA
   Google Scholar
• El-Harazi SM, Feldman RM. Control of intra-ocular inflammation associated with cataract surgery. Curr Opin Ophthalmol 2001;12:4–8
   Google Scholar
• Simone JN, Whitacre MM. Effects of anti-inflammatory drugs following cataract extraction. Curr Opin Ophthalmol 2001;12:63–7
   PubMed Web of Science ®Google Scholar
• Laurell CG, Zetterstrom C. Effects of dexamethasone, diclofenac, or placebo on the inflammatory response after cataract surgery. Br J Ophthalmol 2002;86:1380–4
   PubMed Web of Science ®Google Scholar
• Herbort CP, Jauch A, Othenin-Girard P, et al. Diclofenac drops to treat inflammation after cataract surgery. Acta Ophthalmol Scand 2000;78:421–4
   Google Scholar
• Notivol R, Bertin D, Amin D, et al. Comparison of topical tobramycin–dexamethasone with dexamethasone–neomycin– polymyxin and neomycin–polymyxin–gramicidin for control of inflammation after cataract surgery: results of a multicenter, prospective, three-arm, randomized, double-masked, controlled, parallel-group study. Clin Ther 2004;26:1274–85
   PubMed Web of Science ®Google Scholar
• Hariprasad SM, Blinder KJ, Shah GK, et al. Penetration pharmacokinetics of topically administered 0.5% moxifloxacin ophthalmic solution in human aqueous and vitreous. Arch Ophthalmol 2005;123:39–44
   Google Scholar
• Kim DH, Stark WJ, O’Brien TP, et al. Aqueous penetration and biological activity of moxifloxacin 0.5% ophthalmic solution and gatifloxacin 0.3% solution in cataract surgery patients. Ophthalmology 2005;112: 1992–6
   Google Scholar
• Schlech BA, Blondeau J. Future of ophthalmic anti-infective therapy and the role of moxifloxacin ophthalmic solution 0.5% (VIGAMOX). Surv Ophthalmol 2005;50(Suppl 1):S64–7
   Google Scholar
• McCulley JP, Caudle D, Aronowicz JD, et al. Fourth-generation fluoroquinolone penetration into the aqueous humor in humans. Ophthalmology 2006;113:955–9
   PubMed Web of Science ®Google Scholar
• Ong-Tone L. Aqueous humor penetration of gatifloxacin and moxifloxacin eyedrops given by different methods before cataract surgery. J Cataract Refract Surg 2007;33:59–62
   PubMed Web of Science ®Google Scholar
• Costello P, Bakri SJ, Beer PM, et al. Vitreous penetration of topical moxifloxacin and gatifloxacin in humans. Retina 2006;26:191–5
   PubMed Web of Science ®Google Scholar
• Solomon R, Donnenfeld ED, Perry HD, et al. Penetration of topically applied gatifloxacin 0.3%, moxifloxacin 0.5%, and ciprofloxacin 0.3% into the aqueous humor. Ophthalmology 2005;112: 466–9
   Google Scholar
• Katz HR, Masket S, Lane SS, et al. Absorption of topical moxifloxacin ophthalmic solution into human aqueous humor. Cornea 2005;24:955–8
   PubMed Web of Science ®Google Scholar
• Notivol R, Amin D, Whitling A, et al.; and the International TobraDex Study Group. Prophylactic effectiveness of tobramycindexamethasone eye drops compared with tobramycin/vehicle eye drops in controlling post-surgical inflammation in cataract patients: prospective, randomised, double-masked, two-arm, parallel-group, placebo-controlled, multicentre study. Clin Drug Invest 2004;24:523–33
   Google Scholar
• Laurell CG, Zetterstrom C. Effects of dexamethasone, diclofenac, or placebo on the inflammatory response after cataract surgery. Br J Ophthalmol 2002;86:1380–4
   PubMed Web of Science ®Google Scholar
• Price MO, Price FW Jr, Maclellan D. Effect of gatifloxacin 0.3% and moxifloxacin 0.5% ophthalmic solutions on human corneal epithelium following 2 dosing regimens. J Cataract Refract Surg 2005;31:2137–41
   Google Scholar
• Ritterband DC, Shah MK, Meskin SW, et al. Efficacy and safety of moxifloxacin as an additive in Optisol-GS, a preservation medium for corneal donor tissue. Cornea 2006;25:1084–9
   PubMed Web of Science ®Google Scholar
• Renard G, Adenis JP, Rouland JF, et al. Efficacy and tolerability of a combination of indomethacin and gentamicin for preventing inflammation after cataract surgery. J Fr Ophthalmol 1996;19:689–95
   PubMedGoogle Scholar
• van Endt JJ, Veraart HG, Kramer R, et al. A comparison of two ophthalmic steroid–antibiotic combinations after cataract surgery. Eur J Ophthalmol 1997;7:144–8
   PubMedGoogle Scholar
• Shepherd WF, Fsadni MG, Raj PS. Diclofenac–gentamicin versus Gentamicin Study Group. A clinical evaluation of diclofenac–gentamicin combination eye drops in the control of inflammation after cataract surgery. Ocul Immunol Inflamm 1998;6:13–8
   Google Scholar
• Barraquer RI, Alvarez de Toledo JP, Montane D, et al. Fixed-dose combination of 0.1% diclofenac plus 0.3% tobramycin ophthalmic solution for inflammation after cataract surgery: a randomized, comparative, active treatment-controlled trial. Eur J Ophthalmol 1998;8: 173–8
   Google Scholar
• Russo S, Papa V, Di Bella A, et al. Dexamethasone–netilmicin: a new ophthalmic steroid–antibiotic combination. Efficacy and safety after cataract surgery. Eye 2007;21:58–64
   Google Scholar